Skip to main content
رجوع
PVLA logo

Palvella Therapeutics, Inc.

جودة البيانات: 100%
PVLA
NASDAQ Healthcare Biotechnology
KWD 116.23
▼ KWD 0.81 (-0.69%)
القيمة السوقية: 1.38B
نطاق اليوم
KWD 113.00 KWD 118.64
نطاق 52 أسبوعًا
KWD 18.23 KWD 151.18
حجم التداول
275,035
متوسط 50 يوم / 200 يوم
KWD 103.28 / KWD 71.39
الإغلاق السابق
KWD 117.04

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -78.9 0.3
P/B 22.0 2.9
ROE % -59.4 3.7
Net Margin % 3.8
Rev Growth 5Y % 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 203.920 +75.4%
Low: KWD 143.000 High: KWD 255.000
ربحية السهم المستقبلية
-KWD 3.878
الإيرادات المقدّرة
27000

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 7.276
KWD 7.276 – KWD 7.276
310 M 4
FY2028 -KWD 0.735
-KWD 7.040 – KWD 11.060
130 M 10
FY2027 -KWD 4.985
-KWD 9.326 – -KWD 2.663
25 M 11

النقاط الرئيسية

Earnings declined -193.27% over the past year
Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -10.84M
PEG of 0.01 suggests growth is underpriced

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)-193.27%
FCF Growth (3Y)N/A

الجودة

Return on Equity
-59.37%
ROIC-16.89%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
0.00
Current Ratio7.33
Interest Coverage-3.27

التقييم

P/E Ratio
-78.92
P/B Ratio21.98
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) -193.27% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -17.43M
ROE -59.37% ROA -19.76%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -10.84M
ROIC -16.89% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 7.33
Interest Coverage -3.27 Dividend Yield 0.00%
Valuation
P/E Ratio -78.92 P/B Ratio 21.98
P/S Ratio N/A PEG Ratio 0.01
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.38B Enterprise Value 1.29B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 25.90M 31.42M
Net Income -17.43M 18.69M -33.28M -45.74M
EPS (Diluted) -7.83 14.74 -29.61 -56.69
Gross Profit 0.0 0.0 23.12M 29.05M
Operating Income -14.10M -11.87M -43.47M -51.83M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 88.23M 7.55M 16.52M 153.56M 105.01M
Total Liabilities 25.63M 11.43M 39.70M 102.81M 73.98M
Shareholders' Equity 62.61M -3.88M -23.17M 50.76M 31.03M
Total Debt 0.0 0.0 0.0 14.89M 16.96M
Cash & Equivalents 83.60M 7.35M 16.05M 117.76M 70.44M
Current Assets 88.23M 7.55M 16.52M 127.63M 75.72M
Current Liabilities 12.04M 2.36M 5.78M 50.56M 22.15M